Shengshi Tech's Class 1 New Drug Sentagliptin Approved in China for Type 2 Diabetes Treatment

Dec 03, 2024 16:08 CST Updated 16:08

CGeneTech

Small Molecule Innovative Drug Developer

On December 3, the NMPA website announced that CGeneTech's Class 1 new drug, Sengliptin, has been approved for marketing in China for the treatment of...Type 2 Diabetes（CXHS2300022/3）。

Screenshot source:NMPA Official Website

Seng列汀 is CGeneTechIndependent Research and DevelopmentClass 1 innovative drug, as aNovel Oral DPP-4 InhibitorWith advantages such as high selectivity and strong inhibition.

The approval of Seng列汀 is based on the positive results of a Phase III clinical trial. The results showed that the Seng列汀 50 mg dose group(Low-dose Group)HbA1c at Week 24（HbA1c）Reduced ValueAchieved the primary clinical endpoint, significantly superior to the control group. 28-week Senglietin 100 mg dose group(High-dose Group) also demonstrated good drug safety, with an adverse reaction rate similar to that of the placebo group.

Screenshot source: Insight database

Insight database shows that previously, 9 DPP-4 inhibitor new drugs have been approved for marketing in China, among which there are 3 China-produced DPP-4 inhibitors, respectively.HaiscoCogrelitin,SalubrisFuglitinib andHengruiDapagliflozin.CGeneTechDosenegliptin isThe 4th Product Manufactured in ChinaNew DPP-4 Inhibitor Drug.

Screenshot source: Insight database

Cover Source:Company Logo

Disclaimer:This article is for information sharing only, and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If you have any needs, please consult and contact正规医疗机构.

Editor: Mimu

PR Article Connection: WeChat insightxb

SubmissionWeChat: insightxb; Email: insight@dxy.cn

Diversified functions, traceable data……

Insight Database Web Version Awaits Your Experience

Click to read the original text,ImmediatelyUnlock！